We present a mechanistic population model for the pharmacokinetics of nicotine (NIC), its primary (CYP2A6-generated) metabolite cotinine (COT), and COT’s primary (CYP2A6-generated) metabolite, trans-3′-hydroxycotinine (3HC). Sixty-six subjects received oral deuterium-labeled NIC (NIC-d2, 2 mg), and COT (COT-d4, 10 mg) simultaneously. Frequent plasma/saliva samples were taken for measurement of concentrations of NIC-d2, COT-d2, 3HC-d2, COT-d4, and 3HC-d4. A mechanistic population pharmacokinetic model was fitted to all data simultaneously. Most of the pharmacokinetic parameters found here agree with previous studies and with a previous model-independent analysis of these data. However, 3HC t1/2 was found to be considerably shorter than a previously reported value, possibly because 3HC elimination was saturated with the larger doses used in the previous study. Additionally, the delay in the appearance of COT-d2 in the blood was modeled as a time delay (t1/2 = 12 min) in its release from the liver following NIC-d2 administration. The most important result of the previous model-independent analysis of these data, confirmed here, is that NIC clearance to COT and the 3HC:COT saliva concentration ratio are highly correlated (r = 0.7−0.8). The correlation above support that idea that the 3HC:COT ratio can be used as a predictor of CYP2A6 activity and nicotine clearance. The model-based analysis extends and further justifies this conclusion.
Similar content being viewed by others
Abbreviations
- WRES:
-
population standard deviation units
- PRED:
-
population predictions
References
Dempsey D., Tutka P., Jacob P., III, Allen F., Schoedel K., Tyndale R.F., Benowitz N.L. (2004) Nicotine metabolite ratio as an index of CYP2A6 metabolic activity. Clin. Pharmacol. Ther. 76:64–72
Benowitz N.L., Jacob P., III. (1994). Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56:483–493
Benowitz N.L., Kuyt F., Jacob P., III, Jones R.T., Osman A.L. (1983) Cotinine disposition and effects. Clin. Pharmacol. Ther. 309:139–142
Hukkanen J., Jacob P., III, Benowitz N.L. (2005) Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57:79–115
Benowitz N.L., Jacob P., III, Fong I., Gupta S. (1994) Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268:296–303
Benowitz N.L., Jacob P., III. (2001) Trans-3′-hydroxycotinine: Disposition kinetics, effects and plasma levels during cigarette smoking. Br. J. Clin. Pharmacol. 51:53–59
M. Levi, D. Dempsey, N. L. Benowitz, and L. B. Sheiner. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples. II. Model application. J. Pharmacokinet. Pharmacodyn. DOI: 10.1007/s10928-006-9026-0 (2007).
Curvall M., Elwin C.-E., Kazemi-Vala E., Warholm C., Enzell C.R. (1990) The pharmacokinetics of cotinine in plasma and saliva from nonsmoking healthy volunteers. Eur. J. Clin. Pharmacol. 38:281–287
Benowitz N.L., Jacob P., III, Denaro C., Jenkins R. (1991) Stable isotope studies of nicotine kinetics and bioavailability. Clin. Pharmacol. Ther. 49:270–277
Zevin S., Jacob P., III, Geppetti P., Benowitz N.L. (2000) Clinical pharmacology of oral cotinine. Drug Alcohol Depend. 60:13–18
Jacob P., III, Yu L., Wilson M., Benowitz N.L. (1991) Selected ion monitoring method for determination of nicotine, cotinine, and deuterium-labeled analogs. Absence of an isotope effect in the clearance of (S)-nicotine-3′-3′-d2 in humans. Biol. Mass. Spectrom 20:247–252
Jacob P., III, Shulgin A., Yu L., Benowitz N.L. (1992) Determination of the nicotine metabolite trans-3′-hydroxycotinine in smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J. Chromatogr. 583:145–154
S. L. Beal, and L. B. Sheiner. NONMEM Users Guides. NONMEM Project Group, UCSF, San Francisco, CA, 1992.
Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. (1996) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1010–1015
Jarvis M.J., Russell M.A.H., Benowitz N.L., Feyerabend C. (1988) Elimination of cotinine from body fluids: Implications for noninvasive measurement of tobacco smoke exposure. Am. J. Public Health 78:696–698
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Levi, M., Dempsey, D.A., Benowitz, N.L. et al. Population Pharmacokinetics of Nicotine and Its Metabolites I. Model Development. J Pharmacokinet Pharmacodyn 34, 5–21 (2007). https://doi.org/10.1007/s10928-006-9027-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-006-9027-z